SCHEMBL26108342

SCHEMBL26108342

Cn1c(C2=CCC3(CC2)CCN(C=CC=O)CC3)c(-c2ncc(O[C@H]3CCOC3)cn2)c2c(N)ncnc21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26107952 0.94 — —
SCHEMBL26108434 0.92 KCNH2 (0.30) —
SCHEMBL26108236 0.91 — —
SCHEMBL26106100 0.88 — —
SCHEMBL26108735 0.87 RET (0.31) —
SCHEMBL30582522 0.86 FGFR2 (0.36) —
SCHEMBL26107398 0.84 — —
SCHEMBL26105475 0.84 LRRK2 (0.32) —
SCHEMBL26109846 0.83 KCNH2 (0.36) —
SCHEMBL26108491 0.82 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO claimed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback